BioCryst Pharmaceuticals Valuation
Is BCRX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BCRX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BCRX * (MX$155) is trading below our estimate of fair value (MX$914.98)
Significantly Below Fair Value: BCRX * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BCRX *?
Key metric: As BCRX * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
What is BCRX *'s PS Ratio? | |
---|---|
PS Ratio | 3.8x |
Sales | US$412.58m |
Market Cap | US$1.58b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5.1x |
Enterprise Value/EBITDA | -65.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BCRX *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 10.6x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$25.3b |
NRIX Nurix Therapeutics | 26.8x | 39.1% | US$1.5b |
A214450 PharmaResearch | 6.9x | 24.2% | ₩2.2t |
688276 Changchun BCHT Biotechnology | 7.1x | 26.9% | CN¥11.4b |
BCRX * BioCryst Pharmaceuticals | 3.8x | 15.3% | Mex$1.6b |
Price-To-Sales vs Peers: BCRX * is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (10.6x).
Price to Sales Ratio vs Industry
How does BCRX *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: BCRX * is good value based on its Price-To-Sales Ratio (3.8x) compared to the Global Biotechs industry average (9.3x).
Price to Sales Ratio vs Fair Ratio
What is BCRX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.8x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BCRX *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$299.49 0% | 43.2% | Mex$606.32 | Mex$161.69 | n/a | 11 |
Dec ’25 | n/a | Mex$294.41 0% | 43.3% | Mex$603.45 | Mex$160.92 | n/a | 11 |
Nov ’25 | n/a | Mex$280.77 0% | 44.0% | Mex$582.73 | Mex$135.97 | n/a | 11 |
Oct ’25 | n/a | Mex$280.62 0% | 44.0% | Mex$582.42 | Mex$135.90 | n/a | 11 |
Sep ’25 | Mex$170.00 | Mex$280.62 +65.1% | 44.0% | Mex$582.42 | Mex$135.90 | n/a | 11 |
Aug ’25 | n/a | Mex$249.03 0% | 46.7% | Mex$533.64 | Mex$106.73 | n/a | 11 |
Jul ’25 | n/a | Mex$236.31 0% | 46.7% | Mex$506.39 | Mex$101.28 | n/a | 11 |
Jun ’25 | n/a | Mex$236.31 0% | 46.7% | Mex$506.39 | Mex$101.28 | n/a | 11 |
May ’25 | n/a | Mex$232.60 0% | 46.7% | Mex$505.00 | Mex$101.00 | n/a | 11 |
Apr ’25 | n/a | Mex$232.60 0% | 46.7% | Mex$505.00 | Mex$101.00 | n/a | 11 |
Mar ’25 | Mex$98.86 | Mex$237.35 +140.1% | 46.7% | Mex$515.30 | Mex$103.06 | n/a | 11 |
Feb ’25 | n/a | Mex$237.35 0% | 46.7% | Mex$515.30 | Mex$103.06 | n/a | 11 |
Jan ’25 | n/a | Mex$241.06 0% | 46.2% | Mex$513.23 | Mex$102.65 | n/a | 11 |
Dec ’24 | n/a | Mex$241.06 0% | 46.2% | Mex$513.23 | Mex$102.65 | n/a | 11 |
Nov ’24 | n/a | Mex$274.41 0% | 46.2% | Mex$541.61 | Mex$144.43 | n/a | 10 |
Oct ’24 | n/a | Mex$260.32 0% | 46.2% | Mex$513.78 | Mex$137.01 | n/a | 10 |
Sep ’24 | n/a | Mex$258.14 0% | 47.1% | Mex$512.86 | Mex$136.76 | Mex$170.00 | 10 |
Aug ’24 | n/a | Mex$258.02 0% | 48.1% | Mex$514.32 | Mex$137.15 | n/a | 10 |
Jul ’24 | Mex$120.00 | Mex$259.38 +116.2% | 47.2% | Mex$513.62 | Mex$136.97 | n/a | 10 |
Jun ’24 | n/a | Mex$265.88 0% | 45.8% | Mex$533.38 | Mex$142.23 | n/a | 11 |
May ’24 | n/a | Mex$268.01 0% | 45.5% | Mex$539.29 | Mex$143.81 | n/a | 11 |
Apr ’24 | n/a | Mex$283.83 0% | 41.7% | Mex$550.97 | Mex$146.92 | n/a | 11 |
Mar ’24 | n/a | Mex$283.83 0% | 41.7% | Mex$550.97 | Mex$146.92 | Mex$98.86 | 11 |
Feb ’24 | n/a | Mex$322.95 0% | 36.2% | Mex$580.16 | Mex$193.39 | n/a | 10 |
Jan ’24 | n/a | Mex$331.91 0% | 35.6% | Mex$592.70 | Mex$197.57 | n/a | 10 |
Dec ’23 | n/a | Mex$346.41 0% | 31.8% | Mex$590.47 | Mex$236.19 | n/a | 10 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.